ZYME Zymeworks
- 9.040
- -0.070-0.77%
- 8.940
- -0.100-1.11%
Zymeworks News
Zymeworks (NASDAQ:ZYME) Investors Are Sitting on a Loss of 75% If They Invested Three Years Ago
Subdued Growth No Barrier To Zymeworks Inc.'s (NASDAQ:ZYME) Price
It's not a stretch to say that Zymeworks Inc.'s (NASDAQ:ZYME) price-to-sales (or "P/S") ratio of 13.6x right now seems quite "middle-of-the-road" for companies in the Biotechs industry in the United
Form 144 | Zymeworks(ZYME.US) Insider Proposes to Sell 774.06K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 11, $Zymeworks(ZYME.US)$ Insider Christopher Astle intends to sell 86,294 shares of its common stock on Jun 11, with a total market value of approximately $774.06K. Sour
Sector Update: Health Care Stocks Decline Premarket Monday
Health care stocks were declining premarket Monday as the iShares Biotechnology ETF (IBB) was 0.5% lower and the Health Care Select Sector SPDR Fund (XLV) was down 0.3% recently. Skye Bioscience (SKYE
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy
Zymeworks (ZYME) said Monday that China's health regulator has accepted the Biologics License Application for its second-line experimental treatment of HER2-positive biliary tract cancer, zanidatamab.
Zymeworks' BLA For Zanidatamab For HER2-positive BTC Accepted By CDE In China
Zymeworks Achieves Key Milestone With BLA Acceptance for Zanidatamab in China, Zymeworks to Receive Up to $164M in Milestone Payments
Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat dise
Express News | Zymeworks Inc: Priority Review by FDA With Target Action Date of November 29, 2024
Express News | Zymeworks Inc: Zymeworks Remains Eligible to Receive up to $164 Mln Based on Additional Milestones Plus Royalties on Product Sales
Express News | Zymeworks Inc: Zymeworks Is Entitled to Receive an $8 Mln Milestone Payment From Beigene
Express News | Zymeworks Announces China Nmpa Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
H.C. Wainwright Maintains Zymeworks(ZYME.US) With Hold Rating, Maintains Target Price $10
H.C. Wainwright analyst Robert Burns maintains $Zymeworks(ZYME.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 24.0% and a
Bispecific and Trispecific Antibodies Market to Observe Stupendous Growth by 2035, Predicts DelveInsight | Key Companies - Akeso, Summit Therapeutics, Zymeworks, BeiGene, Jazz Pharmaceuticals, Merus, Roche
DelveInsight's Bispecifics/Trispecifics Market Insights report includes a comprehensive understanding of current treatment practices, emerging...
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the
Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)
Zymeworks Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Ratings for Zymeworks (NASDAQ:ZYME) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below offers a condensed view of their recent r
Express News | HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $10 Price Target
Zymeworks Price Target Cut to $16.00/Share From $17.00 by Citigroup
Zymeworks Price Target Cut to $16.00/Share From $17.00 by Citigroup
Zymeworks Is Maintained at Overweight by Wells Fargo
Zymeworks Is Maintained at Overweight by Wells Fargo
Express News | Wells Fargo Maintains Overweight on Zymeworks, Lowers Price Target to $12
Analysis
Price Target
No Data
